Merck CEO Rob Davis told CNBC’s Jim Cramer that there’s more to the pharmaceutical giant than its lucrative cancer drug, Keytruda.

CNBC’s Jim Cramer delivers his daily Mad Dash. Jimmy Kimmel Breaks Up Reacting to L.A. Wildfires: "We Don't Even Know If It's ...

Stocks in Focus This Week. In this article, we are going to take a look at where Wells Fargo & Company (NYSE:WFC) stands ...

Sean Boyd, the chair of Agnico Eagle Mines (TSX: AEM; NYSE: AEM), recalled when the company’s performance prompted CNN’s Mad ...

Jim Cramer, the host of Mad Money, recently discussed some of the week’s important market events, focusing on earnings ...

The European Union’s top diplomat Kaja Kallas said Ukraine’s allies should work toward lowering the price cap on Russian oil ...

Turkey's Pasifik Holding plans more cooperation in the global technology sector and also seeks to invest in port operations, ...

We recently compiled a list of the 10 Firms Drop on Bearish Statements, Disappointing Earnings. In this article, we are going ...

Kraft Heinz, Ralph Lauren, Opera, Aspen Aerogels, Arbutus, Alaska Air, KKR, and Crown Castle. Special counsel report on ...